Indications:
To minimize the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When selecting or modifying antibacterial therapy, bacterial culture and susceptibility testing results should be considered. In the absence of such data, empirical therapy may be instituted based on local epidemiology and pathogen susceptibility patterns.

Bacterial culture and susceptibility tests should be performed before treatment to isolate and identify causative pathogens and determine their susceptibility to levofloxacin. Therapy with levofloxacin may be initiated before obtaining these test results; once results become available, appropriate therapy should be selected.

As with other drugs in this class, some strains of Pseudomonas aeruginosa may rapidly develop resistance during treatment with levofloxacin. Regular bacterial culture and susceptibility testing should be performed during treatment to monitor the continued susceptibility of pathogens to the antimicrobial agent and to promptly detect any emerging resistance. Levofloxacin oral formulation and injection are indicated for the treatment of mild, moderate, and severe infections caused by susceptible strains of the designated microorganisms in adults (≥18 years). Levofloxacin injection should be administered when intravenous therapy offers clinical advantages (e.g., when oral administration is not tolerated).

Strength:0.25g、0.5g

National Drug Approval Number:H20183513、H20183514